Updated EMILIA Phase III Trial Results Confirm Increase in Overall Survival
Study: HPV Testing Can Predict Precancers For Nearly Two Decades Following Exam
Kyprolis Demonstrates Overall Response Following FDA Accelerated Approval
Trastuzumab Increases Risks Of Congestive Heart Failure
Breast Density Does Not Raise Breast Cancer Death Rates
Amgen Halts Phase III Trial Of Ganitumab Plus Gemcitabine
Spectral Mammography “Like Color vs. Black & White TV”
Study Reveals Racial Disparities In Surgical Prostate Care
2,000 Breast Cancer Recurrence Biomarker Candidates Discovered
NCI Approved CTEP Trials For the Month of August
FDA Approves Afinitor Tablets For Advanced Breast Cancer
Afinitor Suspension Approved For Rare Pediatric Brain Tumor
FDA Approves Xtandi For Late-Stage Castration-Resistant Prostate Cancer
Trending Stories
- Columbia’s cancer center becomes collateral damage in Trump’s war on antisemitism
- What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - Caught in the crossfire: The critical threats facing cancer centers, research, and patient care
- Kennedy announces massive cuts, centralization at HHS—NCI and FDA hit
Also this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology - Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills - DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated
